A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

PHASE4CompletedINTERVENTIONAL
Enrollment

167

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Purpura, Thrombocytopaenic, Idiopathic
Interventions
DRUG

Eltrombopag olamine

Thrombopoietin receptor agonist

Trial Locations (34)

4012

GSK Investigational Site, Debrecen

6720

GSK Investigational Site, Szeged

9023

GSK Investigational Site, Győr

10021

GSK Investigational Site, New York

13353

GSK Investigational Site, Berlin

14033

GSK Investigational Site, Caen

20132

GSK Investigational Site, Milan

20162

GSK Investigational Site, Milan

33604

GSK Investigational Site, Pessac

35128

GSK Investigational Site, Padua

36100

GSK Investigational Site, Vicenza

40138

GSK Investigational Site, Bologna

40225

GSK Investigational Site, Düsseldorf

40479

GSK Investigational Site, Düsseldorf

45122

GSK Investigational Site, Essen

54600

GSK Investigational Site, Lahore

75300

GSK Investigational Site, Karachi

81241

GSK Investigational Site, Munich

81377

GSK Investigational Site, Munich

94010

GSK Investigational Site, Créteil

125167

GSK Investigational Site, Moscow

141008

GSK Investigational Site, Ludhiana

193024

GSK Investigational Site, Saint Petersburg

395002

GSK Investigational Site, Surat

411004

GSK Investigational Site, Pune

630087

GSK Investigational Site, Novosibirsk

632004

GSK Investigational Site, Vellore

Unknown

GSK Investigational Site, Hradec Králové

GSK Investigational Site, Shatin, New Territories

775 20

GSK Investigational Site, Olomouc

128 08

GSK Investigational Site, Prague

463-712

GSK Investigational Site, Seongnam-si Gyeonggi-do

135-710

GSK Investigational Site, Seoul

137-701

GSK Investigational Site, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY